Elevage Medical Technologies

Nuclera is a biotechnology company specializing in an automated protein prototyping system aimed at enhancing drug discovery processes. Its eProtein Discovery system enables researchers to rapidly produce and test high-quality, soluble, and active proteins, significantly accelerating protein projects. By integrating technology such as cell-free protein synthesis and digital microfluidics, Nuclera provides a high-throughput platform for automated protein access. This innovative approach allows scientists to obtain reliable proteins within a short timeframe, facilitating faster progress in their research and contributing to more efficient drug development efforts.

Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

4basebio AG is a biotechnology company based in Heidelberg, Germany, specializing in the manufacturing of DNA products for therapeutic applications and research. The company provides a range of research and diagnostic tools, utilizing its proprietary enzymes, including RNA reverse transcriptase, DNA polymerase, and DNA primase. 4basebio serves the fast-growing gene therapy market and aims to enable advancements in medical science and patient care. Formerly known as Expedeon AG, the company rebranded to 4basebio AG in January 2020, reflecting its focus on life science technology and DNA manufacturing. Its products cater to both European and international markets, addressing the needs of researchers and healthcare professionals.

Elucid, located in the Boston biotech and medtech hub, specializes in enhancing the accuracy and cost-effectiveness of cardiovascular diagnostic imaging through machine learning. Its flagship product, ElucidVivo, is the first FDA-cleared software that evaluates plaque vulnerability from a single computed tomography angiography (CTA) scan, aiding in the assessment of heart attack and stroke risk as well as treatment selection. The company also collaborates with pharmaceutical firms, healthcare providers, and research organizations to offer quantitative image analysis services. By applying artificial intelligence to vascular diagnostics, Elucid aims to improve patient outcomes while providing a non-invasive and economically efficient means of capturing critical health information, thereby supporting cardiovascular pathologists in delivering comprehensive clinical insights.